PCI Biotech Holding ASA (FRA:4QG)

Market Cap	239.50K -94.6%
Revenue (ttm)	394.60K -21.9%
Net Income	-1.73M
EPS	-0.05
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,339
Average Volume	467
Open	0.0100
Previous Close	0.0100
Day's Range	0.0100 - 0.0100
52-Week Range	0.0068 - 0.1505
Beta	n/a
RSI	46.96
Earnings Date	May 8, 2026

About PCI Biotech Holding ASA

PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development of technologies and novel therapies through its photochemical technology platform. The company’s technology platform consists of a proprietary small molecule photosensitiser and a light source; and develops photochemical lysis (PCL) comprising light-triggered cell lysis, which enhances yield and purity in viral vector manufacturing, as well as photochemical internalisation (PCI), inducing light-triggered intracellular release for various therapeutic modalities. It ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2007
• Employees: 5
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4QG

Financial Performance

In 2024, PCI Biotech Holding ASA's revenue was 6.74 million, an increase of 125.25% compared to the previous year's 2.99 million. Losses were -16.42 million, -19.19% less than in 2023.

Financial numbers in NOK